Stroke After High-Dose/Adjuvanted Influenza Vaccines in U.S. Older Adults; 2016-2019

Yun Lu¹, PhD; Kathryn Matuska², BA; Yuxin Ma², MS; Layo Laniyan², BAH; Yoganand Chillarige², MPA; Steven A. Anderson¹, PhD; Richard A. Forshee¹, PhD

Affiliations: (1) Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland; (2) Acumen, LLC Burlingame, California

Address correspondence to Yun Lu, MS, PhD, 10903 New Hampshire Avenue, Silver Spring, MD 20993;

email: Yun.Lu@fda.hhs.gov

ABSTRACT

Importance

A recent study from the U.S. Food and Drug Administration investigated the risk of stroke following COVID-19 bivalent and high-dose/adjuvanted influenza vaccines among older adults (individuals \geq 65 years) who experienced stroke after vaccination in the 2022-2023 season. The study found a small but significant association between stroke and high-dose/adjuvanted influenza vaccination in the Medicare fee-for-service (FFS) population.

Objective

To evaluate stroke risk following high-dose/adjuvanted influenza vaccines in three historical influenza seasons.

Design, Setting, and Participants

The analysis included Medicare beneficiaries ≥ 65 years who had a stroke outcome after receiving a highdose or adjuvanted influenza vaccine in three influenza seasons 2016-2019. For each season, the study period began on the first Sunday of August and ended one day before the start of the subsequent season (e.g., Sunday, August 7, 2016 through Saturday, August 5, 2017). A self-controlled case series analysis was performed to compare the risk of stroke in risk intervals (1-21 and 22-42 days) to a control interval (43-90 days).

Exposures

High-dose/adjuvanted influenza vaccines.

Main Outcomes and Measures

Non-hemorrhagic stroke (NHS), transient ischemic attack (TIA), NHS and/or TIA (NHS/TIA), and hemorrhagic stroke (HS).

Results

We observed 29,730 stroke cases in 2016-2017; 34,518 cases in 2017-2018; and 36,869 cases in 2018-2019. In 2016-2017, the primary analysis found a statistically significant association for HS during the 22-42 day risk window (incidence rate ratio (IRR)=1.14, 95% confidence interval (CI) 1.02–1.28; Risk Difference (RD)/100,000 doses=0.84, 95% CI 0.14–1.54) compared to the control interval. However, no significant primary analysis results were identified in 2017-2018 or 2018-2019.

Conclusions and Relevance

We did not observe clear, consistent evidence of increased stroke risk following high-dose or adjuvanted influenza vaccination across the three seasons 2016-2019. The statistically significant associations we identified were not consistently observed across outcomes, risk windows, age subgroups, or seasons. The clinical significance of any potential risk of stroke following vaccination must be carefully considered together with the significant benefits of receiving an influenza vaccination.

Introduction

A recent study from the U.S. Food and Drug Administration investigated the risk of stroke following COVID-19 bivalent and high-dose/adjuvanted influenza vaccines among older adults (individuals \geq 65 years) who experienced stroke after vaccination.¹ The self-controlled case series (SCCS) study did not find clear, consistent evidence of a risk of stroke in the days shortly following COVID-19 bivalent vaccination. However, a small but significant association between stroke and high-dose/adjuvanted influenza vaccination was detected in the Medicare fee-for-service (FFS) population in the 2022-2023 season. To determine if an increase in stroke risk occurred in prior years following influenza vaccination in Medicare beneficiaries, we conducted this follow-up historical analysis of the 2016-2017, 2017-2018, and 2018-2019 seasons.

Methods

Using a SCCS design, the risk of four incident (no events in 365 days prior) stroke outcomes – nonhemorrhagic stroke (NHS), transient ischemic attack (TIA), a combined outcome of NHS and/or TIA (NHS/TIA), and hemorrhagic stroke (HS) – following exposure to a high-dose or adjuvanted influenza vaccine were evaluated, first among persons \geq 65 years (primary analysis) and then by age subgroup (65-74, 75-84, 85+ years).¹ Fixed risk windows (1-21 days and 22-42 days) were compared to a postvaccination control window (43-90 days). For each season, the study period began on the first Sunday of August and ended one day before the start of the subsequent season (e.g., Sunday, August 7, 2016 through Saturday, August 5, 2017). Our study population consisted of beneficiaries aged \geq 65 years who did not reside in a nursing home facility and were continuously enrolled in FFS Medicare plans for at least a year prior to vaccination. We estimated incidence rate ratios (IRR) for each season using conditional Poisson regression and calculated risk difference (RD) per 100,000 doses. We also conducted a retrospective temporal scan to identify clusters of increased stroke risk within 90 days following vaccination.

Results

We observed 29,730 stroke cases in 2016-2017; 34,518 cases in 2017-2018; and 36,869 cases in 2018-2019 (Table 1). In 2016-2017, the primary analysis found a statistically significant association for HS during the 22-42 day risk window (IRR=1.14, 95% confidence interval (CI) 1.02–1.28; RD/100,000 doses=0.84, 95% CI 0.14–1.54) compared to the control interval. However, no significant primary analysis results were identified in 2017-2018 or 2018-2019.

The age subgroup analyses showed significant associations for HS during the 22-42 day risk window in the 65-74 age subgroup in 2016-2017 (IRR=1.24, 95% CI 1.02–1.51; RD/100,000 doses=0.83, 95% CI 0.07–1.59), and in the 75-84 age subgroup in 2017-2018 (IRR=1.19, 95% CI 1.03–1.37; RD/100,000 doses=1.56, 95% CI 0.25–2.87). In 2018-2019 we identified significant associations in the 85+ age subgroup for NHS (IRR=1.17, 95% CI 1.06–1.29; RD/100,000 doses=6.40, 95% CI 2.34–10.47) and NHS/TIA (IRR=1.14, 95% CI 1.06–1.23, RD/100,000 doses=8.66, 95% CI 3.51–13.81) during the 1-21 day risk window.

Discussion

Overall, we did not observe clear, consistent evidence of increased stroke risk following high-dose or adjuvanted influenza vaccination across the three seasons 2016-2019. The statistically significant associations we identified were not consistently observed across outcomes, risk windows, age subgroups, or seasons. We did not adjust for multiple testing, because the system was designed to be sensitive to potential safety signals. The temporal scan identified case clusters in control windows for several outcomes in 2017-2018 and 2018-2019, which conflicts with the signals identified through the SCCS

framework. While studies in the literature show that influenza infections increase the risk of stroke, our study only included vaccinated cases and did not account for the protective effect of vaccination against infections.^{2,3} The clinical significance of any potential risk of stroke following vaccination must be carefully considered together with the significant benefits of receiving an influenza vaccination.^{4,5}

Acknowledgements:

To Henry T. Zhang¹, PhD for contributions to methodology development, results review, letter writing and review.

To Jeffrey A. Kelman³, MD for contributions to methodology development and results review.

To Nathan Duma², PhD; Yiyun Chiang², MPH; and Hai Lyu², MS, for contributions to methodology development, data collection and analysis, and results review.

To Gita Nadimpalli², PhD for contributions to methodology development.

Author's contributions: Yun Lu¹, PhD; Richard A. Forshee¹, PhD; and Steven A. Anderson¹, PhD contributed to the study conception and design, data interpretation, letter writing and review. Kathryn Matuska², BA; Yuxin Ma², MS; Layo Laniyan², BAH, and Yoganand Chillarige², MPA, contributed to study design, data collection and analysis, letter writing and review. All authors have seen and approved the manuscript.

Affiliations: (1) Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland; (2) Acumen, LLC Burlingame, California; (3) Centers for Medicare & Medicaid Services, Washington, DC

Institutional Review Board (IRB) and Patient Informed Consent

This study did not require full FDA IRB committee review and approval because it was determined to be exempt from the requirements of 45 CFR Part 46; 46.104(d)(2) under the 2018 Common Rule. The use of Medicare administrative data was approved by CMS privacy board under a data use agreement. The analyses utilized only existing records and the subjects cannot be identified. Patient consent was not required since our study was based on CMS claims data and thus does not include factors necessitating patient consent.

Potential Conflicts of Interest

None of the authors reported potential conflicts of interest.

Funding Source

This work was supported by the Food and Drug Administration (FDA) as part of the SafeRx Project, a joint initiative of the Centers for Medicare & Medicaid Services and FDA.

Data Sharing

All data produced in the present work are contained in the manuscript. Access to original datasets is not available to protect patient information.

References

- 1. Lu Y, Matuska K, Nadimpalli G, et al. Evaluation of Stroke Risk Following COVID-19 mRNA Bivalent Vaccines Among U.S. Adults Aged ≥65 Years. 2023:2023.2010.2010.23296624.
- 2. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *The New England journal of medicine*. 2004;351(25):2611-2618.
- 3. Ohland J, Warren-Gash C, Blackburn R, et al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.* 2020;25(17).
- 4. Asghar. Influenza vaccination and risk of stroke: self-controlled case-series study. Vaccine. 2015.
- 5. Sen A. Influenza vaccination and risk for cardiovascular events: a nationwide self-controlled case series study. *BMC Cardiovascular Disease*. 2021.

| | High-Dose or Adjuvanted Influenza Vaccines | | | | | | | |
|---|--|------------------|-------------|-------------|--|--|--|--|
| | 2016-2017 | | | | | | | |
| | NHS | TIA | NHS/TIA | HS | | | | |
| # of Eligible Vaccinated | 8,175,412 | 8,175,412 | 8,175,412 | 8,175,412 | | | | |
| Person Days | 341,745,121 | 341,745,121 | 341,745,121 | 341,745,121 | | | | |
| Cases in First Risk Window (1-21 days) | 1,736 | 1,464 | 3,135 | 470 | | | | |
| Cases in Second Risk Window (22-42 days) | 1,708 | 1,506 | 3,134 | 549 | | | | |
| Cases in Control Window (43-90 days) | 4,131 | 4,131 3,375 7,34 | | 1,144 | | | | |
| | 2017-2018 | | | | | | | |
| | NHS | TIA | NHS/TIA | HS | | | | |
| # of Eligible Vaccinated | 9,600,332 | 9,600,332 | 9,600,332 | 9,600,332 | | | | |
| Person Days | 401,473,253 | 401,473,253 | 401,473,253 | 401,473,253 | | | | |
| Cases in First Risk Window (1-21 days) | 2,297 | 1,861 | 4,060 | 711 | | | | |
| Cases in Second Risk Window (22-42 days) | 2,433 | 1,937 | 4,255 | 765 | | | | |
| Cases in Control Window (43-90 days) | 5,635 | 4,360 | 9,782 | 1,761 | | | | |
| | 2018-2019 | | | | | | | |
| | NHS | TIA | NHS/TIA | HS | | | | |
| # of Eligible Vaccinated | 10,499,741 | 10,499,741 | 10,499,741 | 10,499,741 | | | | |
| Person Days | 439,128,469 | 439,128,469 | 439,128,469 | 439,128,469 | | | | |
| Cases in First Risk Window (1-21 days) | 2,103 | 1,700 | 3,734 | 536 | | | | |
| Cases in Second Risk Window (22-42 days) | 2,078 | 1,737 | 3,722 | 600 | | | | |
| Cases in Control Window (43-90 days) | 4,880 | 3,974 | 8,681 | 1,343 | | | | |

Table 1. Observed Outcome Counts and Person Days Among Eligible High-Dose or Adjuvanted Influenza Vaccinated Medicare Beneficiaries ≥65 Years, by Influenza Season.

Abbreviations: HS, hemorrhagic stroke; NHS, non-hemorrhagic stroke; TIA, transient ischemic attacks.

Figure 1. Risk of Stroke Following High-Dose or Adjuvanted Influenza Vaccines: Summary of Primary Analysis and Age Subgroup Analysis by Influenza Season.

| Event and Window | 2016 - 2 | 2016 - 2017: High-Dose/Adjuvanted Influenza Vaccine | | 2017 - 2 | 2017 - 2018: High-Dose/Adjuvanted Influenza Vaccine | | | 2018 - 2019: High-Dose/Adjuvanted Influenza Vaccine | | |
|--|----------------------|---|---------------------------------------|----------------------|---|---------------------------------------|----------------------|---|---------------------------------------|--|
| listorical Influenza Analysis Ion-Hemorrhagic Stroke | Rate (Risk, Control) | IRR (95 % CI) | | Rate (Risk, Control) | IRR (95 % CI) | | Rate (Risk, Control) | IRR (95 % CI) | | |
| 21 Day Risk Window | (1.01, 1.05) | 1.02 (0.96, 1.08) | | (1.14, 1.22) | 0.97 (0.92, 1.02) | | (0.95, 0.97) | 1.02 (0.97. 1.08) | | |
| 2-42 Dav Risk Window | (1.00, 1.05) | 0.99 (0.94, 1.05) | | (1.14, 1.22) | 1.02 (0.97, 1.07) | | (0.94, 0.97) | 1.02 (0.97, 1.08) | | |
| | (1.00, 1.05) | 0.99 (0.94, 1.05) | | (1.21, 1.22) | 1.02 (0.97, 1.07) | | (0.94, 0.97) | 1.01 (0.96, 1.06) | | |
| ransient Ischemic Attack | | | | | | | | | | |
| -21 Day Risk Window | (0.85, 0.86) | 1.03 (0.97, 1.09) | | (0.92, 0.95) | 1.01 (0.96, 1.07) | | (0.77, 0.79) | 1.02 (0.96, 1.08) | | |
| 2-42 Day Risk Window | (0.88, 0.86) | 1.05 (0.99, 1.12) | | (0.96, 0.95) | 1.05 (0.99, 1.11) | + | (0.79, 0.79) | 1.03 (0.98, 1.09) | | |
| Non-Hemorrhagic Stroke or | | | | | | | | | | |
| Transient Ischemic Attack | | | | | | | | | | |
| 1-21 Day Risk Window | (1.83, 1.87) | 1.02 (0.98, 1.06) | | (2.01, 2.12) | 0.99 (0.96, 1.03) | | (1.69, 1.72) | 1.02 (0.98, 1.06) | | |
| 2-42 Day Risk Window | (1.83, 1.87) | 1.01 (0.97, 1.06) | | (2.11, 2.12) | 1.03 (0.99, 1.07) | ÷ | (1.69, 1.72) | 1.02 (0.98, 1.06) | | |
| Hemorrhagic Stroke | | | | | | | | | | |
| 1-21 Day Risk Window | (0.27, 0.29) | 0.99 (0.88, 1.12) | | (0.35, 0.38) | 0.98 (0.89, 1.08) | | (0.24, 0.27) | 0.95 (0.85, 1.07) | | |
| 22-42 Day Risk Window | (0.32, 0.29) | 1.14 (1.02, 1.28)** | · | (0.38, 0.38) | 1.07 (0.97, 1.17) | | (0.24, 0.27) | 1.03 (0.93, 1.15) | | |
| | , | | | | | | | | | |
| Age Subgroup Analysis Non-Hemorrhagic Stroke 1-21 Day Risk Window | Rate (Risk, Control) | IRR (95 % CI) | | Rate (Risk, Control) | IRR (95 % CI) | | Rate (Risk, Control) | IRR (95 % CI) | | |
| Age 65-74 | (0.60, 0.61) | 1.04 (0.93, 1.16) | | (0.68, 0.70) | 1.03 (0.94, 1.13) | | (0.57, 0.58) | 1.03 (0.94, 1.13) | | |
| Age 75-84 | (1.12, 1.19) | 1.00 (0.91, 1.09) | , <u> </u> | (1.25, 1.36) | 0.97 (0.90, 1.05) | , <u> </u> | (1.03, 1.14) | 0.94 (0.87, 1.03) | · · · · · · | |
| Age 85+ | (2.09, 2.17) | 1.01 (0.91, 1.13) | · | (2.43, 2.66) | 0.93 (0.85, 1.02) | · | (2.10, 1.90) | 1.17 (1.06, 1.29)** | · · · · · · · · · · · · · · · · · · · | |
| 2-42 Day Risk Window | (2.05, 2.17) | 1.01 (0.91, 1.13) | 1 | (2.43, 2.00) | 0.95 (0.85, 1.02) | | (2.10, 1.90) | 1.17 (1.00, 1.29) | | |
| Age 65-74 | (0.61, 0.61) | 1.05 (0.94, 1.16) | | (0.68, 0.70) | 1.00 (0.92, 1.10) | | (0.56, 0.58) | 1.00 (0.91, 1.10) | · • • · · · | |
| Age 75-84 | (1.11, 1.19) | 0.97 (0.88, 1.06) | | (1.36, 1.36) | 1.04 (0.96, 1.12) | | (1.09, 1.14) | 1.00 (0.92, 1.08) | | |
| Age 85+ | (1.98, 2.17) | 0.96 (0.87, 1.07) | | (2.64, 2.66) | 1.01 (0.93, 1.10) | | (1.92, 1.90) | 1.05 (0.95, 1.16) | | |
| Transient Ischemic Attack 1-21 Day Risk Window | | | | | | | | | | |
| Age 65-74 | (0.57, 0.57) | 1.03 (0.92, 1.15) | | (0.57, 0.61) | 0.97 (0.88, 1.07) | | (0.55, 0.56) | 1.02 (0.93, 1.12) | | |
| Age 75-84 | (0.99, 0.98) | 1.05 (0.95, 1.16) | · · · · · | (1.06, 1.10) | 1.01 (0.92, 1.10) | | (0.86, 0.92) | 0.97 (0.88, 1.06) | | |
| Age 85+ | (1.47, 1.53) | 0.99 (0.88, 1.12) | · · · · · · · · · · · · · · · · · · · | (1.81, 1.74) | 1.09 (0.98, 1.21) | | (1.35, 1.25) | 1.11 (0.99, 1.25) | · · · · · | |
| 22-42 Day Risk Window | | , | | , | | | | | | |
| Age 65-74 | (0.58, 0.57) | 1.04 (0.94, 1.16) | | (0.61, 0.61) | 1.04 (0.94, 1.14) | · · · · · · · · · · · · · · · · · · · | (0.54, 0.56) | 0.99 (0.90, 1.09) | | |
| Age 75-84 | (1.02, 0.98) | 1.07 (0.98, 1.18) | | (1.14, 1.10) | 1.07 (0.99, 1.17) | · | (0.93, 0.92) | 1.05 (0.96, 1.14) | · · · · · · | |
| Age 85+ | (1.52, 1.53) | 1.02 (0.91, 1.15) | | (1.72, 1.74) | 1.02 (0.92, 1.13) | · | (1.30, 1.25) | 1.07 (0.95, 1.21) | | |
| | , | | | | | | | | | |
| Non-Hemorrhagic Stroke or Transient Ischemic Attack 1-21 Dav Risk Window | | | | | | | | | | |
| Age 65-74 | (1.14, 1.16) | 1.03 (0.96, 1.11) | ⊢ ● | (1.22, 1.28) | 1.00 (0.94. 1.07) | | (1.10, 1.12) | 1.02 (0.96. 1.10) | | |
| Age 75-84 | (2.07, 2.12) | 1.02 (0.96, 1.09) | | (2.25, 2.41) | 0.98 (0.93, 1.04) | | (1.85, 2.02) | 0.96 (0.90, 1.02) | | |
| Age 85+ | (3.49, 3.61) | 1.01 (0.93, 1.09) | | (4.14, 4.30) | 0.99 (0.93, 1.07) | | (3.39, 3.10) | 1.14 (1.06, 1.23)** | · · · · · | |
| 2-42 Day Risk Window | (00, 0.01) | | | (3.14, 4.30) | 0.00 (0.00, 1.07) | | (0.00, 0.10) | | - | |
| Age 65-74 | (1.16, 1.16) | 1.04 (0.96, 1.12) | | (1.25, 1.28) | 1.01 (0.95, 1.08) | | (1.07, 1.12) | 0.99 (0.92, 1.06) | | |
| Age 75-84 | (2.08, 2.12) | 1.01 (0.95, 1.08) | | (2.45, 2.41) | 1.05 (1.00, 1.12) | | (1.97, 2.02) | 1.02 (0.96, 1.09) | | |
| Age 85+ | (3.43, 3.61) | 0.99 (0.92, 1.07) | — | (4.22, 4.30) | 1.01 (0.94, 1.08) | | (3.15, 3.10) | 1.05 (0.97, 1.14) | + | |
| lemorrhagic Stroke | | | | | | | | | | |
| | | | | | | | | | | |
| 21 Day Risk Window | | | | | | | | | | |
| Age 65-74 | (0.16, 0.17) | 1.00 (0.81, 1.24) | | (0.18, 0.21) | 0.86 (0.71, 1.04) | | (0.15, 0.14) | 1.06 (0.86, 1.30) | | |
| Age 75-84 | (0.32, 0.32) | 1.04 (0.86, 1.26) | • | (0.42, 0.45) | 1.02 (0.87, 1.19) | • • ••• | (0.27, 0.33) | 0.90 (0.76, 1.08) | • | |
| Age 85+ | (0.53, 0.62) | 0.90 (0.72, 1.14) | • • | (0.77, 0.80) | 1.05 (0.87, 1.26) | · · · · · · · · · · · · · · · · · · · | (0.51, 0.56) | 0.91 (0.73, 1.14) | | |
| 2-42 Day Risk Window | | | | | | | | | | |
| Age 65-74 | (0.20, 0.17) | 1.24 (1.02, 1.51)** | • | (0.20, 0.21) | 0.98 (0.82, 1.17) | • | (0.14, 0.14) | 1.03 (0.84, 1.26) | • | |
| Age 75-84 | (0.36, 0.32) | 1.17 (0.98, 1.40) | · | (0.47, 0.45) | 1.19 (1.03, 1.37)** | | (0.37, 0.33) | 1.14 (0.98, 1.33) | | |
| Age 85+ | (0.61, 0.62) | 1.01 (0.81, 1.25) | · | (0.78, 0.80) | 0.99 (0.83, 1.18) | • | (0.49, 0.56) | 0.85 (0.69, 1.06) | • • | |

Abbreviations: Rate - Risk, Event rate per 100,000 person-days in the risk window, Rate - Control, Event rate per 100,000 person-days in the control window,

IRR, Incident rate ratio: 95% CI, 95% Confidence Interval; HD/AD, High-dose influenza vaccine/Adjuvanted influenza vaccine, IRR's were obtained using Conditional Poisson regression comparing the risk to the control interval; ** Indicates statistical significance